Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD), has announced it will report its second quarter 2024 financial results on August 7, 2024. The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results. Investors can access the call via phone or through a live webcast available on the company's website. A replay of the webcast will be archived for future reference. This announcement indicates Kymera's commitment to transparency and regular communication with investors regarding its financial performance and progress in developing new small molecule medicines using TPD technology.
Kymera Therapeutics (NASDAQ: KYMR), un'azienda biofarmaceutica in fase clinica focalizzata sulla degradazione proteica mirata (TPD), ha annunciato che riporterà i suoi risultati finanziari del secondo trimestre 2024 il 7 agosto 2024. L'azienda ospiterà una conferenza telefonica alle 8:30 a.m. ET nello stesso giorno per discutere i risultati. Gli investitori potranno accedere alla chiamata telefonicamente o tramite un webcast in diretta disponibile sul sito web dell'azienda. Una registrazione del webcast sarà archiviata per riferimento futuro. Questo annuncio evidenzia l'impegno di Kymera per la trasparenza e la comunicazione regolare con gli investitori riguardo alle sue performance finanziarie e ai progressi nello sviluppo di nuovi medicinali a piccole molecole utilizzando la tecnologia TPD.
Kymera Therapeutics (NASDAQ: KYMR), una empresa biofarmacéutica en etapa clínica centrada en la degradación proteica dirigida (TPD), ha anunciado que reportará sus resultados financieros del segundo trimestre de 2024 el 7 de agosto de 2024. La empresa llevará a cabo una conferencia telefónica a las 8:30 a.m. ET el mismo día para discutir los resultados. Los inversores podrán acceder a la llamada por teléfono o a través de un webcast en vivo disponible en el sitio web de la empresa. Se archivará una grabación del webcast para referencia futura. Este anuncio indica el compromiso de Kymera con la transparencia y la comunicación regular con los inversores sobre su rendimiento financiero y el progreso en el desarrollo de nuevos medicamentos de moléculas pequeñas utilizando la tecnología TPD.
Kymera Therapeutics (NASDAQ: KYMR), 표적 단백질 분해(TPD)에 중점을 둔 임상 단계의 생명공학 회사는 2024년 8월 7일에 2024년 2분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 8시 30분 ET에 결과를 논의하기 위해 전화 회의를 개최합니다. 투자자들은 전화 또는 회사 웹사이트에서 제공되는 라이브 웹캐스트를 통해 전화 회의에 접속할 수 있습니다. 웹캐스트의 녹음은 향후 참조를 위해 보관될 것입니다. 이번 발표는 Kymera의 재무 성과 및 TPD 기술을 활용한 새로운 소분자 의약품 개발에 관한 투자자와의 정기적인 소통과 투명성에 대한 의지를 보여줍니다.
Kymera Therapeutics (NASDAQ: KYMR), une entreprise biopharmaceutique en phase clinique spécialisée dans la dégradation ciblée des protéines (TPD), a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le 7 août 2024. L'entreprise tiendra une conférence téléphonique le même jour à 8h30 ET pour discuter des résultats. Les investisseurs peuvent accéder à l'appel par téléphone ou via un webinaire en direct disponible sur le site Web de l'entreprise. Un enregistrement du webinaire sera archivé pour référence future. Cet annonce met en évidence l'engagement de Kymera envers la transparence et la communication régulière avec les investisseurs concernant sa performance financière et ses progrès dans le développement de nouveaux médicaments à petites molécules utilisant la technologie TPD.
Kymera Therapeutics (NASDAQ: KYMR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Proteinabbau (TPD) konzentriert, hat bekannt gegeben, dass es seine Finanzergebnisse für das zweite Quartal 2024 am 7. August 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu diskutieren. Investoren können die Konferenz telefonisch oder über ein Live-Webcast auf der Website des Unternehmens abrufen. Eine Aufzeichnung des Webcasts wird für zukünftige Referenz archiviert. Diese Ankündigung zeigt Kymeras Engagement für Transparenz und regelmäßige Kommunikation mit Investoren bezüglich ihrer finanziellen Leistung und des Fortschritts bei der Entwicklung neuer niedermolekularer Medikamente unter Verwendung der TPD-Technologie.
- None.
- None.
Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report second quarter 2024 financial results on August 7, 2024, and will host a conference call at 8:30 a.m. ET.
To access the August 7 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company’s conference call will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (previously Twitter) or LinkedIn.
Investor and Media Contact: Justine Koenigsberg Vice President, Investor Relations investors@kymeratx.com media@kymeratx.com 857-285-5300 |
FAQ
When will Kymera Therapeutics (KYMR) report its Q2 2024 financial results?
What time is Kymera Therapeutics' (KYMR) Q2 2024 earnings call scheduled for?
How can investors access Kymera Therapeutics' (KYMR) Q2 2024 earnings call?
Will there be a replay available for Kymera Therapeutics' (KYMR) Q2 2024 earnings call?
